PET imaging of redox and energy states in stroke-like episodes of MELAS

Mitochondrion

Volumn 9, Issue 2, 2009, Pages 144-148

  Ikawa, Masamichi ^a   Okazawa, Hidehiko ^a   Arakawa, Kenichiro ^a   Kudo, Takashi ^a   Kimura, Hirohiko ^a   Fujibayashi, Yasuhisa ^a   Kuriyama, Masaru ^a   Yoneda, Makoto ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Functional imaging; MELAS; Over reduction state; Oxidative stress; PET; Stroke like episodes

Indexed keywords

ARGININE; DEXAMETHASONE; DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE) CU 62; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLYCEROL; LACTIC ACID; PYRUVIC ACID; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; APHASIA; ARTICLE; BLOOD FLOW; BRAIN DAMAGE; CASE REPORT; CLINICAL FEATURE; CONSCIOUSNESS DISORDER; CONVULSION; FEMALE; GLUCOSE METABOLISM; HEADACHE; HEMIPARESIS; HUMAN; HUMAN TISSUE; MELAS SYNDROME; MUSCLE WEAKNESS; NAUSEA; OXIDATIVE STRESS; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; WEIGHT REDUCTION;

ADULT; BRAIN; FEMALE; GLUCOSE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MELAS SYNDROME; OXIDATIVE STRESS; POSITRON-EMISSION TOMOGRAPHY; REGIONAL BLOOD FLOW;

EID: 62549084242     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mito.2009.01.011     Document Type: Article

References (28)

1. Bandy B., and Davison A.J. Mitochondrial mutations may increase oxidative stress: implications for carcinogenesis and aging?. Free Radic. Biol. Med. 8 (1990) 523-539
2. Buettner G.R. Spin trapping: ESR parameters of spin adducts. Free Radic. Biol. Med. 3 (1987) 259-303
3. Dearling J.L., Lewis J.S., Mullen G.E., Welch M.J., and Blower P.J. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. J. Biol. Inorg. Chem. 7 (2002) 249-259
4. Fowler J.S., and Ido T. Initial and subsequent approach for the synthesis of 18FDG. Semin. Nucl. Med. 32 (2002) 6-12
5. Fujibayashi Y., Taniuchi H., Yonekura Y., Ohtani H., Konishi J., and Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J. Nucl. Med. 38 (1997) 1155-1160
6. Fujibayashi Y., Cutler C.S., Anderson C.J., McCarthy D.W., Jones L.A., Sharp T., Yonekura Y., and Welch M.J. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl. Med. Biol. 26 (1999) 117-121
7. Fujii T., Okuno T., Ito M., Mutoh K., Horiguchi Y., Tashiro H., and Mikawa H. MELAS of infantile onset: mitochondrial angiopathy or cytopathy?. J. Neurol. Sci. 103 (1991) 37-41
8. Goto Y., Nonaka I., and Horai S. A mutation in the tRNA (Leu) (UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature 348 (1990) 651-653
9. Iizuka T., Sakai F., Suzuki N., Hata T., Tsukahara S., Fukuda M., and Takiyama Y. Neuronal hyperexcitability in stroke-like episodes of MELAS syndrome. Neurology 59 (2002) 816-824
10. Indo H.P., Davidson M., Yen H.C., Suenaga S., Tomita K., Nishii T., Higuchi M., Koga Y., Ozawa T., and Majima H.J. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion 7 (2007) 106-118
11. Ishikawa K., Kimura S., Kobayashi A., Sato T., Matsumoto H., Ujiie Y., Nakazato K., Mitsugi M., and Maruyama Y. Increased reactive oxygen species and anti-oxidative response in mitochondrial cardiomyopathy. Circ. J. 69 (2005) 617-620
12. Koga Y., Akita Y., Nishioka J., Yatsuga S., Povalko N., Tanabe Y., Fujimoto S., and Matsuishi T. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology 64 (2005) 710-712
13. Lewis J.S., Sharp T.L., Laforest R., Fujibayashi Y., and Welch M.J. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. J. Nucl. Med. 42 (2001) 655-661
14. Lewis J.S., Herrero P., Sharp T.L., Engelbach J.A., Fujibayashi Y., Laforest R., Kovacs A., Gropler R.J., and Welch M.J. Delineation of hypoxia in canine myocardium using PET and copper (II)-diacetyl-bis(N(4)-methylthiosemicarbazone). J. Nucl. Med. 43 (2002) 1557-1569
15. Manwaring N., Jones M.M., Wang J.J., Rochtchina E., Howard C., Mitchell P., and Sue C.M. Population prevalence of the MELAS A3243G mutation. Mitochondrion 7 (2007) 230-233
16. McKenzie M., Liolitsa D., and Hanna M.G. Mitochondrial disease: mutations and mechanisms. Neurochem. Res. 29 (2004) 589-600
17. Molnár M.J., Valikovics A., Molnár S., Trón L., Diószeghy P., Mechler F., and Gulyás B. Cerebral blood flow and glucose metabolism in mitochondrial disorders. Neurology 55 (2000) 544-548
18. Nishioka J., Akita Y., Yatsuga S., Katayama K., Matsuishi T., Ishibashi M., and Koga Y. Inappropriate intracranial hemodynamics in the natural course of MELAS. Brain Dev. 30 (2008) 100-105
19. Obata A., Yoshimi E., Waki A., Lewis J.S., Oyama N., Welch M.J., Saji H., Yonekura Y., and Fujibayashi Y. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann. Nucl. Med. 15 (2001) 499-504
20. Ohama E., Ohara S., Ikuta F., Tanaka K., Nishizawa M., and Miyatake T. Mitochondrial angiopathy in cerebral blood vessels of mitochondrial encephalomyopathy. Acta. Neuropathol. 74 (1987) 226-233
21. Pang C.Y., Lee H.C., and Wei Y.H. Enhanced oxidative damage in human cells harboring A3243G mutation of mitochondrial DNA: implication of oxidative stress in the pathogenesis of mitochondrial diabetes. Diabetes Res. Clin. Pract. 54 (2001) S45-56
22. Pavlakis S.G., Phillips P.C., DiMauro S., De Vivo D.C., and Rowland L.P. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann. Neurol. 16 (1984) 481-488
23. Rusanen H., Majamaa K., and Hassinen I.E. Increased activities of antioxidant enzymes and decreased ATP concentration in cultured myoblasts with the 3243A->G mutation in mitochondrial DNA. Biochim. Biophys. Acta. 1500 (2000) 10-16
24. Shelly M.J., Kelly P., and O'Connell M.J. FDG-PET imaging in the investigation of homonymous hemianopia in a patient with MELAS syndrome. Clin. Nucl. Med. 32 (2007) 479-480
25. Shigenaga M.K., Gimeno C.J., and Ames B.N. Urinary 8-hydroxy-2'-deoxyguanosine as a biological marker of in vivo oxidative DNA damage. Proc. Natl. Acad. Sci. USA 86 (1989) 9697-9701
26. Uusimaa J., Moilanen J.S., Vainionpää L., Tapanainen P., Lindholm P., Nuutinen M., Löppönen T., Mäki-Torkko E., Rantala H., and Majamaa K. Prevalence, segregation, and phenotype of the mitochondrial DNA 3243A>G mutation in children. Ann. Neurol. 62 (2007) 278-287
27. Yoneda M., Maeda M., Kimura H., Fujii A., Katayama K., and Kuriyama M. Vasogenic edema on MELAS: a serial study with diffusion-weighted MR imaging. Neurology 53 (1999) 2182-2184
28. Zhang J., Yoneda M., Naruse K., Borgeld H.J., Gong J.S., Obata S., Tanaka M., and Yagi K. Peroxide production and apoptosis in cultured cells carrying mtDNA mutation causing encephalomyopathy. Biochem. Mol. Biol. Int. 46 (1998) 71-79